Alnylam Pharmaceuticals (ALNY) Receivables - Other (2020 - 2021)
Alnylam Pharmaceuticals' (ALNY) quarterly Receivables - Other came in at $500.0 million in Q2 2021, little changed quarter-over-quarter from $500.0 million in Q1 2021.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Receivables - Other (2020 - 2021) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has reported Receivables - Other for 2 consecutive years, with $500.0 million the latest figure, recorded in Q2 2021.
- For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $500.0 million; the trailing twelve-month figure through Jun 2021 stood at $500.0 million (changed N/A YoY), and the FY2020 full-year result was $500.0 million, changed N/A from the prior year.
- Receivables - Other steadied at $500.0 million in Q2 2021 per ALNY's latest filing, from $500.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $500.0 million in Q3 2020 and bottomed at $500.0 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 500.00 Mn |
| Mar 31, 2021 | 500.00 Mn |
| Dec 31, 2020 | 500.00 Mn |
| Sep 30, 2020 | 500.00 Mn |